SynthesisThe Lancet. Microbe2025
Therapeutics for Nipah virus disease: a systematic review to support prioritisation of drug candidates for clinical trials.
Synthesis in The Lancet. Microbe, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- A highly potent, stable, and safe dePEGylated lipopeptide against Nipah virus and related henipaviruses.Emerging microbes & infections · 2026Article
- Discovery of Quercetin as a Potential Entry Inhibitor of Nipah Virus: A Path Toward Antiviral Therapy.International journal of molecular sciences · 2026Article
- Community engagement strategies for preventing recurrent Nipah virus outbreaks in Bangladesh and India: adapting a framework for outbreak preparedness and response.Journal of global health · 2026Article
- Progression of nipah virus infection in the African green monkey: Role of macrophages and dendritic cells in early virus spread.iScience · 2026Article
- Nipah virus preparedness in a One Health framework: Implications for Europe.One health (Amsterdam, Netherlands) · 2026Review
- International risk assessment of Nipah virus outbreak and medium-long-term prevention and control prospects in China.MedScience · 2026Article
- Nipah Virus Encephalitis: Pathogenetic Aspects and Current Therapeutic Strategies.Pathogens (Basel, Switzerland) · 2026Review
- Efficacy of the nucleoside analog 4'-Fluorouridine against Nipah virus in the Syrian hamster model.PLoS pathogens · 2026Article
- Oral 4'fluorouridine provides postexposure protection against lethal Nipah virus infection.bioRxiv : the preprint server for biology · 2026Article
- Exploratory Evaluation of Peptide-Based Immunization Targeting Fusion Glycoprotein-Derived Epitopes of Nipah Virus in Murine Model.Vaccines · 2026Article
- Nipah virus infection: what clinicians need to know.Le infezioni in medicina · 2026Review
- A risk-gate mechanistic-ecological framework for assessing emergence potential of henipa-related viruses.Frontiers in microbiology · 2026Article
- Henipavirus evidence gaps: a Rapid Research Needs Appraisal.BMJ public health · 2026Article
- Integrating Prevention and Response at the Crossroads of Henipavirus Preparedness, Hendra@30 Conference, 2024.Emerging infectious diseases · 2026Article
- Review
- Indirect ELISAs Based on Nipah and Langya Virus Proteins for Detecting Antibodies in Animals.Infectious microbes & diseases · 2025Article
- Mechanistic insights into Nipah virus 5' UTR functionality reveal an antiviral target.The Journal of general virology · 2025Article
- Review
- A deep learning and molecular modeling approach to repurposing Cangrelor as a potential inhibitor of Nipah virus.Scientific reports · 2025Article
- Design and Preliminary Immunogenicity Evaluation of Nipah Virus Glycoprotein G Epitope-Based Peptide Vaccine in Mice.Vaccines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Nipah virus disease is a bat-borne zoonosis with person-to-person transmission, a case-fatality rate of 38-75%, and well recognised potential to cause a pandemic. The first reported outbreak of Nipah virus disease occurred in Malaysia and Singapore in 1998, which has since been followed by multiple outbreaks in Bangladesh and India. To date, no therapeutics or vaccines have been approved to treat Nipah virus disease, and only few such candidates are in development. In this Review, we aim to assess the safety and efficacy of the therapeutic options (monoclonal antibodies and small molecules) for Nipah virus disease and other henipaviral diseases to support prioritisation of drug candidates for further evaluation in clinical trials. At present, sufficient evidence exists to suggest trialling 1F5, m102.4, and remdesivir (alone or in combination) for prophylaxis and early treatment of Nipah virus disease. In addition to well designed clinical efficacy trials, in-vivo pharmacokinetic-pharmacodynamic studies are needed to optimise the selection and dosing of therapeutic candidates in animal challenge and natural human infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.